NCT02389842View on ClinicalTrials.gov

PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclib

PHASE1CompletedINTERVENTIONAL
Enrollment

79

Participants

Timeline

Start Date

March 25, 2015

Primary Completion Date

October 31, 2018

Study Completion Date

May 26, 2021

Conditions
Advanced Solid TumoursBreast Cancer
Interventions
DRUG

Palbociclib + Taselisib / Pictilisib

Trial Locations (2)

SM2 5PT

The Royal Marsden NHS Foundation Trust, London

M20 4BX

The Christie NHS Foundation Trust, Manchester

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Institute of Cancer Research, United Kingdom

OTHER

collaborator

Roche Pharma AG

INDUSTRY

collaborator

Pfizer

INDUSTRY

lead

Royal Marsden NHS Foundation Trust

OTHER

NCT02389842 - PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclib | Biotech Hunter | Biotech Hunter